Clinical Trial Update: New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial update describing a new tablet formulation and dosing regimen of balsalazide disodium in patients with mildly to moderately active ulcerative coli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• BALSALAZIDE DISODIUM (balsalazide disodium)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED